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Not Eliminate Host Anti-Donor T Cells that Cause Graft
Rejection on Its Withdrawal
Patricia A. Taylor, Ryan M. Kelly, Nick D. Bade, Michelle J. Smith, Heather E. Stefanski,
Bruce R. BlazarThe immunomodulator FTY720 (FTY) is beneficial in models of graft-versus-host disease, solid organ trans-
plantation, and autoimmunity and has been approved for use in patients with multiple sclerosis. FTY modifies
the homing and migration of many cell types. We report that FTY has profound positive and negative effects
on allogeneic bone marrow (BM) engraftment in sublethally irradiated recipients. FTY increased donor he-
matopoietic progenitors in the BM, resulting in high donor engraftment in the B cell, myeloid cell, and natural
killer cell, but not T cell, lineages. Donor T cell progenitors within the thymus of FTY-treated recipients were
dramatically reduced, resulting in a lack of donor T cell reconstitution. In addition to preventing the ingress of
donor (and host) T cell progenitors, FTY prevented the egress of fully functional host CD41CD82 and
CD42CD81 thymocytes that on cessation of FTYadministration were able to exit from the thymus and con-
tribute to a rapid and complete rejection of a well-established donor BM graft. When used in combination
with anti-CD40L mAbs to block the CD40L:CD40 costimulatory pathway, FTY markedly enhanced anti-
CD40L mAb-mediated alloengraftment promotion. In contrast to FTY alone, the combination of anti-
CD40L mAb and FTY resulted in a surprisingly stable, multilineage, long-term donor chimerism. These
data illustrate FTY’s profound migration modulating effects and suggest a use in combinatorial therapy in
achieving stable alloengraftment under nonmyeloablative conditions.
Biol Blood Marrow Transplant 18: 1341-1352 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Thymopoiesis, Bone marrow transplantation, Animal modelINTRODUCTION
FTY720 (FTY), a synthetic immunomodulator
derived from a metabolite of the fungus Isaria sinclairii,
is a high-affinity agonist for 4 of the 5 known sphingo-
sine 1-phosphate receptors. On phosphorylation, FTY
binds to sphingosine 1-phosphate receptors critically
involved in calcium mobilization, cell survival, cyto-
skeletal rearrangements, cell motility, and cell migra-
tion [1-6]. FTY increases lymphocyte responsiveness
to chemokines that contribute to lymphocytePediatric Blood and Marrow Transplantation, University
nnesota, Minneapolis, Minnesota.
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oi.org/10.1016/j.bbmt.2012.06.007sequestration from circulation and trapping in lymph
nodes (LNs) and Peyer’s patches [7]. FTY inhibits
both thymic ingress of early thymic progenitors
(ETPs) and egress of mature single positive T cells
[8,9]. FTY augments C-X-C chemokine receptor
type 4 (CXCR4)-dependent, stromal cell–derived
factor 1–mediated BM homing of infused donor BM
stem cells [10].
FTY is effective in promoting solid organ allograft
survival and inhibiting autoimmune disease in various
experimental animal models and recently has been
approved for use in patients with relapsing or remitting
multiple sclerosis [1-3,6,11,12]. Studies by our group
and others have indicated that FTY inhibits graft-
versus-host disease (GVHD) by multiple mechanisms
without abrogating a graft-versus-leukemia effect
[13-16]. Because FTY inhibits GVHD while
retaining the graft-versus-leukemia effect, suggesting
a potential for clinical translation, we felt it important
to examine FTY’s effect on engraftment, thymopoie-
sis, and immune reconstitution in recipients of
nonmyeloablative allogeneic bone marrow (BM)
transplantation (BMT). Although the cell migration
and homing effects of FTY have been studied1341
1342 Biol Blood Marrow Transplant 18:1341-1352, 2012P. A. Taylor et al.extensively under normal homeostatic conditions, they
have not been examined in irradiated recipients of
allogeneic BMT.
Because of potential homing/migration perturba-
tion by total body irradiation (TBI) and the presence
of host antidonor effector T cells, the effects of FTY
on engraftment, thymopoiesis, and immune reconsti-
tution in sublethally irradiated allogeneic BMT recip-
ients cannot be predicted with any certainty based
on the results of previous studies. In nonmyeloablated
recipients, the outcome of allogeneic BMT is a precar-
ious balance between engraftment of donor stem cells
and host antidonor rejection by residual competent
host T cells. FTYmight be expected to have certain ef-
fects on both the donor cell inoculum and the host
antidonor immune response, but the net outcome of
those effects is difficult to predict. In the present study,
we found that FTY, used as a single agent, had pro-
found migration-modifying effects on both donor
and host cells that resulted in both a positive and, sur-
prisingly, a negative impact on engraftment. However,
when used in combination with the known engraft-
ment promoter anti-CD40L mAb, FTY was of addi-
tive benefit resulting in increased engraftment that
was multilineage, stable, and long term. These results
suggest that the combined administration of anti-
CD40L mAb with FTY may be highly useful in the
clinical setting for inhibiting GVHD lethality and
promoting alloengraftment.MATERIALS AND METHODS
Mice
Female BALB/c (H2d, thy1.2), C57BL/6 (H2b,
thy1.2; termed B6), C57BL/6 CD45.1 congenics, and
B6.PL-Thy1a/CyJ (H2b, thy1.1; termed B6 thy1.1)
were purchased from Jackson Laboratory or the Na-
tional Institutes of Health. Mice were housed in a spe-
cific pathogen-free facility in microisolator cages and
used at 8-12 weeks of age. All mouse experiments
were approved by the University of Minnesota’s Insti-
tutional Animal Care and Use Committee.
BMT
For allogeneic BMT, B6 thy1.1, B6 thy1.2, or B6
CD45.1 recipients were sublethally irradiated with
5.0 Gy TBI by x-ray on day 21 and infused with
10  106 BALB/c T cell–depleted (TCD) BM cells
on day 0. For low-dose TBI, B6 mice received 1.0
or 2.0 Gy TBI on day 21 and 40  106 non-TCD
BALB/c BM cells on day 0. For congenic studies,
B6 CD45.2 recipients received 1.0 Gy TBI on
day 21 and 10  106 B6 CD45.1 TCD BM cells
on day 0. FTY (Novartis, Basel, Switzerland) at 3.0
mg/kg (a dose reportedly effective for GVHD inhibi-
tion [16]) or sterile water was administered daily byoral gavage during days 0-14 or days 0-28. Mice
were monitored daily for survival and weighed twice
weekly for the first month, then once weekly thereaf-
ter. In some experiments, mice were given anti-CD4
mAb (clone GK1.5; rat IgG2b) and anti-CD8
mAb (clone 2.43; rat IgG2b), 400 mg/dose i.p., on
days 22, 0, and 4 relative to BM infusion to ensure
an engrafted control. In one experiment, anti-thy1.1
(clone 1A14; mouse IgG2a) and/or anti-NK1.1 (clone
PK136; mouse IgG2a), 400 mg/dose i.p. on days 30,
33, and 36, was administered to FTY-treated B6
thy1.1 recipients engrafted with BALB/c thy1.2 BM
to selectively deplete residual host T and natural
killer (NK) cells, respectively. In other experiments,
some mice received anti-CD40L mAb (clone MR-1;
hIgG) i.p. on days 21 to 15, then 3 times a week
up to day 28 (400 mg/dose).
Isolation of Common Lymphoid Progenitors and
Coculture with OP-9DL1
BM was harvested from B6 recipients on day 30
after sublethal TBI and transplantation with BALB/c
BM. The mice had been treated with either anti-
CD4 and anti-CD8 mAbs or oral FTY. All mice
were verified to be high-level donor chimeras
(.94%) by phenotyping of peripheral blood leuko-
cytes (PBLs) on day 29. BM was combined for each
group, and lineage depletion was performed by incu-
bation with PE-labeled antibodies to NK1.1, CD19,
CD4, CD8, CD3, CD11b, and CD11c (eBioscience,
San Diego, CA), followed by incubation with anti-
PE beads and depletion on a magnetic column (Milte-
nyi Biotec, Auburn, CA). Cells were then stained with
PE-CY7 labeled Sca-1, allophycocyanin-labeled ckit,
and PE-labeled H-2Kb. Donor common lymphoid
progenitors (CLPs) were isolated by sorting on
PE2ckitloScal-1lo cells and cultured on OP-9DL1
cells. OP-9DL1 (provided by Juan-Carlos Zuniga-
Pflucker, University of Toronto, Sunnybrook Re-
search Institute, Toronto, Ontario, Canada) is a BM
stromal cell line transduced with Delta-like 1 (DL1)
that provides key signals for T cell lineage commit-
ment and T cell differentiation in in vitro cultures in
the absence of a thymus. T lineage cells were generated
as described previously, with modifications [17]. In
brief, CLPs were seeded on a 60%-80% confluent
monolayer of OP9-DL1 cells at densities ranging
from 1.25e4 to 7.25e4 cells/plate. The tissue culture
media, aMEM (Gibco, Grand Island, NY), was supple-
mented with 20% heat-inactivated FBS (HyClone,
Logan, UT), 100 U/mL of penicillin (Sigma-Aldrich,
St Louis, MO), 100 mg/mL of streptomycin (Sigma-
Aldrich), 5 ng/mL of murine IL-7 (R&D Systems,
Minneapolis, MN), and 5 ng/mL of human FLT3L
(R&D Systems). Cells were maintained as predomi-
nantly double-negative (DN) stage 2 (DN2) and DN
stage 3 (DN3) T cell precursors from day 14 of
Biol Blood Marrow Transplant 18:1341-1352, 2012 1343FTY in Engraftmentcoculture. Cells were phenotyped every 3-5 days start-
ing on day 7 of culture.
Phenotyping
For determination of donor chimerism, PBLs were
collected by facial vein bleed at the indicated time
points and incubated with fluoresceinated antibodies
to H2b, H2d, CD4, CD8, CD11b, DX5, CD45.1,
CD45.2, and CD19 (eBioscience and BDPharmingen,
San Diego, CA). In some experiments, spleens, LNs,
thymi, and BM from tibias and femurs were harvested
at the indicated time points, and single-cell suspen-
sions were obtained, enumerated, and phenotyped as
for PBLs. To quantify donor stem cells (lin2Sca-
11ckit1) and CLPs (lin2Sca-1lockitlo) in the BM,
cells were harvested from both tibias and femurs,
enumerated, and stained with fluoresceinated anti-
bodies to CD45.2, TCR-b, CD8, TCR-gd, CD11b,
CD11c, DX5 or NK1.1, CD19, gran-1, TER119,
ckit, and Sca-1. To quantify donor ETPs
(lin2ckithiCD252CD441) in the thymus, thymocytes
were enumerated and stained with fluoresceinated an-
tibodies CD45.2, TCRb, CD8, TCRgd, CD11b,
CD11c, DX5 or NK1.1, CD19, gran-1, TER119,
ckit, CD25, and CD44. Phenotyping was performed
on a FACScalibur or Fortessa flow cytometer (BD
Biosciences, San Jose, CA) and analyzed with FlowJo
software (TreeStar, Ashland, OR). For chimerism
assessment, 10,000 events were analyzed for each
sample. For quantification of stem cells, CLPs, and
ETPs, between 1  106 and 2  106 events were
analyzed for each sample.
Statistics
Group comparisons were done using the Student t
test. A P value\.05 was considered to indicate statisti-
cal significance.RESULTS
FTY Transiently Increases Allogeneic Donor
Engraftment
To determine the effect of FTY on allogeneic BM
engraftment in non-myeloablated recipients, B6 mice
were sublethally irradiated on day21 and given alloge-
neic BALB/c BMonday 0.Mice received FTY at 3mg/
kg daily by oral gavage from day 0 to day 28, a dose and
schedule that have been reported to be highly effective
in inhibiting GVHD [16] or for a shorter period of 2
weeks which typically covers the period of initial allo-
geneic engraftment in thismodel [18].Controlmice re-
ceived sterile distilled water. PBLs were phenotyped at
5 weeks and 3 months after BMT for determination of
allogeneic donor engraftment. A 2-week or 4-week
course of FTY greatly increased donor chimerism,from 5% in controls to 73% or 84%, respectively,
when evaluated at 5 weeks (Figure 1A). However, en-
graftment declined or was lost entirely in most mice
when PBL engraftment was reassessed at 3 months
after BMT (Figure 1A). The average donor chimerism
declined from 73% at 5 weeks to 23% at 3 months in
mice receiving a 2-week course of FTY and from
84% at 5 weeks to 22% at 3 months in mice receiving
a 4-week course of FTY. High-level donor chimeras
were more likely to retain their graft although not
even an engraftment level of.95% at 5 weeks ensured
durable engraftment in all mice.FTY Promotes Engraftment of Donor B Cells,
Myeloid Cells, and NK Cells, but Not Donor
T Cells
Multilineage PBL phenotyping at the cessation of
FTY treatment on day 28 revealed that although vigor-
ous donor CD191 B, CD11b1 myeloid, and DX51
NK cell engraftment was present in FTY-treated
mice, donor and host T cells were strikingly absent
(Figure 1B and data not shown). Chimerism was also
examined in spleen, LN, and BM at 1 month after
transplantation. Similar to blood, FTY resulted in ro-
bust engraftment of donor B cells and myeloid cells,
but not donor T cells, at 1 month after transplantation
in secondary lymphoid organs and BM (Figure 1C).
Similar to blood, host T cells were markedly reduced
in number in spleen, LN, and BM in FTY-treated
mice. Rejected water-treated control mice had very
few host B cells in PBLs, spleen, LN, and BM, indicat-
ing delayed B cell reconstitution as a result of radiation
injury to host stem cells.
The vigorous donor B cell and myeloid cell en-
graftment coupled with the lack of donor T cell recon-
stitution in the periphery in FTY-treated mice
suggested a specific block in donor thymopoiesis.
Evaluation of the thymus at 1 month confirmed
a lack of both donor and host thymopoiesis in FTY-
treated mice. Although rejected water-treated BMT
controls showed evidence of resumption of host thy-
mopoiesis by 1 month, as indicated by an average of
27  106 CD4CD8 double-positive (DP) thymocytes,
constituting 87% of total thymocytes, FTY-treated
mice had an average of only 1.5 106 DP thymocytes,
constituting only 17% of total thymocytes
(Figure 1D). An average of 73% of thymocytes in
FTY-treated mice were host CD41 or CD81 single-
positive (SP) T cells (Figure 1D), whereas a normal
non-BMT control mouse had 94  106 DP thymo-
cytes, constituting 85% of total thymocytes (data not
shown). These data indicate that FTY blocked both
donor and host thymopoiesis and resulted in retention
of host SP T cells within the thymus, consistent with
FTY’s previously reported effect on blocking thymo-
cyte egress [9,19].
Figure 1. FTY results in transient allogeneic donor engraftment in the B cell and myeloid cell lineages, but not in the T cell lineages. B6 mice were
irradiated with 5.0 Gy TBI on day 21 and infused with 10  106 TCD BALB/c BM on day 0. FTY (3 mg/kg/day) or water was administered orally for
2 weeks (A) or 4 weeks (A-D) from day 0. (A) PBLs were phenotyped for percentage of donor class I1 cells at 5 weeks and 3 months. n 5 47-52
mice/group, pool of 4 experiments. *P\.05, FTY versus H20; P^\.05, 5 weeks versus 3 months. (B) On day 28 after BMT, PBLs were phenotyped
for percentage of donor and host CD191 B, CD11b1 myeloid, and CD41 and CD81 T cells. n 5 7-8 mice/group. P^\.05, donor H20 versus donor
FTY; *P\.05, host H20 versus host FTY. (C) Absolute numbers of donor and host cells of each cell lineage from spleen, peripheral LN pool, and tibias and
femurs (BM) harvested 28 days after BMT. n5 6 mice/group. P^\.05, donor H20 versus donor FTY; *P\.05, host H20 versus host FTY. (D) Thymi were
harvested 28 days after BMT. Shown are the absolute thymocyte numbers of each of the indicated cell populations. n 5 8 mice/group. *P\.05, FTY
versus H20. Data are mean 6 1 standard error of the mean (SEM).
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The increased engraftment in FTY-treated mice
could be due to increased chemokine-mediated BM
homing of donor stem cells, as reported previously
[10], or to decreased host antidonor T cell responses.
To distinguish between these 2 possibilities, FTY
was assessed in sublethally irradiated recipients of con-
genic BM in which host antidonor responses are
absent. B6 CD45.2 mice received 1.0 Gy TBI on
day21 and B6 CD45.1 BM cells on day 0. At 5 weeks,
FTY increased donor congenic chimerism from 27%
to 60%, and in contrast to FTY’s effect on allogeneic
engraftment, donor chimerism was stable when reas-
sessed at 3 months (Figure 2). Similar to the allogeneic
data, PBL T cell percentages were low at 5 weeks
(\2% of total PBLs; data not shown), although nor-
malized by 3 months (average of 35% of total PBLs;
data not shown) suggesting a transient block in donor
thymopoiesis. Together with the allogeneic data, these
data indicate that FTY had a positive effect on donorBM stem cell engraftment and a negative effect on
thymopoiesis.
FTY IncreasesDonor StemCell Homing toHost
BMCompartment but Blocks Thymopoiesis and
Prevents Egress of Host SP T Cells
Our data indicating that FTY increased congenic
engraftment and promoted robust allogeneic engraft-
ment of B, myeloid, and NK cells early after BMT
were consistent with reports that FTY supports BM
homing of donor stem cells [10,20,21]. The blocking
of thymopoiesis and delayed allogeneic graft
rejection were also consistent with reports indicating
that FTY can block both thymus ingress of T cell
progenitors and egress of mature T cells [8,9,19].
Therefore, we hypothesized that although FTY
increased the homing of donor stem cells to the host
BM compartment, CLPs would be trapped in the
BM, resulting in a reduction of ETPs in the thymus
with a resultant block in thymopoiesis. Experiments
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Figure 2. FTY results in increased stable congenic donor engraftment.
B6 CD45.2 mice were irradiated with 1.0 Gy TBI on day21 and infused
with 10 106 TCD congenic B6 CD45.1 BM on day 0. FTYor water was
administered from day 0 to day 28. PBLs were phenotyped for percent-
age of donor CD45.11 cells at 5 weeks and 3 months. N 5 26 mice/
group, pool of 3 experiments. *P \ .05, FTY versus H20. Data are
mean 6 1 SEM.
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(lin2Sca-11ckit1), including donor CLPs (lin2Sca-
1lockitlo), from whence ETPs arise in the BM, and
ETPs (lin2ckithiCD252CD441) in the thymus. For
these experiments, an engrafted BMT control was
deemed a more relevant comparator than rejectedFigure 3. FTY increases donor stem cell homing to the host BM cavity. B6 CD
 106 TCD allogeneic BALB/c CD45.1 BM on day 0. To ensure an engrafted con
and day14 (designated TCD). FTYwas administered on day 0 to day 28. Mice de
CD45.11lineage2Scal-11ckit1 stem cell and CD45.11lineage2Sca-1lockitlo CL
contour plot of donor1 lineage2 BM cells in 1 representative mouse of 5 in co
counts for 5 individual mice per group. The horizontal bar indicates the meanwater-treated BMT mice, because donor stem cells
cannot be detected in the latter. To ensure an en-
grafted control using the same TBI and allogeneic
cell dose parameters as used in previous experiments,
control mice received injections of anti-CD4 and
anti-CD8 mAbs on day22, day 0, and day14, a strat-
egy that depletes host T cells and results in stable high-
level donor engraftment. At the cessation of a 4-week
course of FTY, donor chimerim was assessed. Mice
with similarly high levels of donor chimerism (92%-
97%) were specifically selected for stem cell, CLP,
and ETP enumeration. Despite having similar total
BM counts, FTY-treated mice had 4.9-fold more
donor lin2Sca-11ckit1 stem cells and 2.8-fold more
donor CLPs than controls (Figure 3).
Although increased numbers of donor stem cells
were seen in theBMat day 28, thymopoiesiswas greatly
impaired in FTY-treated mice, as evidenced by the low
total thymocyte number with a.99% reduction in the
number of donor lin2ckithiCD252CD441 ETPs
(Figure 4A-C). FTY-treated mice had an average of
only 4.1  106 total thymocytes, compared with
121.9  106 total thymocytes in engrafted BMT con-
trols (Figure 4B). Moreover, 98% of thymocytes in45.2 mice were irradiated with 5.0 Gy TBI on day21 and infused with 10
trol, anti-CD4 and anti-CD8mAbs were administered on day22, day 0,
termined to have.92% donor PBLs on day 28 were evaluated for donor
P numbers in both femurs and tibias on day 29. (A) A ckit versus Sca-1
ntrol versus FTY-treated mice. (B) BM, donor stem cell, and donor CLP
. *P\.05.
Figure 4. FTY blocks T cell progenitor thymic ingress and mature host T cell thymic egress. A separate cohort of mice as described in the legend to
Figure 3 were evaluated for total thymocyte and ETP numbers and thymic phenotype on day 30 (A-D) and thymocyte number and phenotype at 3 months
after BMT (E). (A) A representative CD4/CD8 plot illustrating that most thymocytes are donor DP in TCD control, indicative of normal thymopoiesis,
whereas most thymocytes are host SP in FTY-treated, engrafted mice indicative of blockage of thymopoiesis on day 28 after BMT. (B and C) Numbers of
total thymocytes (B) and donor ETPs (C) on day 28 after BMT. The y-axis is a log scale. n 5 4-5 mice/group. (D) Total numbers of each thymocyte cell
population. The y-axis is a log scale for donor cell populations. n 5 4-5 mice/group. (E) Thymocyte numbers at 3 months after BMT, showing that host
thymopoiesis was recovered in FTY-treatedmice, whereas most thymocytes in TCD controls were of donor origin. n5 5mice/group. *P\.001;^ P\.05;
NS, not significant (P . .05).
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(Figure 4A andD). In striking contrast, 98% of thymo-
cytes in controls were of donor origin, 88% of which
were CD4CD8 DP cells, indicative of vigorous donor
thymopoiesis (Figure 4A and D). These data indicate
that FTY promoted donor stem cell and progenitor
cell homing to the host BM compartment, but also pre-
vented the ingress of donorETPs to the thymus, result-
ing in a near-absence of donor thymopoiesis. These
data also suggest that FTY prevented the egress of
host SP thymocytes from the thymus, given the virtual
absence of host SP T cells in secondary lymphoid or-
gans in FTY-treated mice at this time.
Although both donor and host thymopoiesis were
nearly absent in FTY-treated mice at 4 weeks, the
blockage was not permanent. When evaluated at 3
months (2 months after discontinuation of FTY),
host thymopoiesis had fully recovered, as indicated
by a high thymocyte number with a high proportion
of CD4CD8 DP thymocytes (Figure 4E).CLPs from FTY-Treated Mice Have the Capacity
to Differentiate into T Cell Progenitors
To evaluate the ability of the CLPs from FTY-
treated allogeneic recipients to differentiate into T
cell progenitors, CLPs were isolated 30 days after
BMT from high-level donor chimeric mice that had
been treated with anti-CD4 mAb and anti-CD8
mAb or FTY or from normal, non-BMT BALB/c
controls. CLPs were cultured on OP-9DL1 cells to
induce in vitro differentiation and maturation of
CLPs, simulating thymic stromal interactions
in vivo, through the earliest stages of T cell develop-
ment. The OP-9DL system enables assessment of the
T cell differentiation potential of CLPs obtained
from FTY-treated mice. The earliest T cells are
CD42CD82 DN cells. DN stage 1 (DN1) cells
(CD441ckit1) progress to DN2 cells (CD251) and
begin to rearrange the b-chain locus, and then to
DN3 cells (CD44lockitlo). On productive rearrange-
ment of the b-chain locus and loss of CD25 expres-
sion, DN3 cells progress to DN stage 4 (DN4)
cells. Similar to TCD allogeneic recipients and
non-BMT controls, CLPs isolated on day 30 from
sublethally irradiated FTY-treated engrafted alloge-
neic recipients differentiated on OP-9DL cells into
primarily DN1 and DN2 cells by day 11 of culture
(Figure 5). By day 16, cultures contained predomi-
nantly DN3 cells. DN4 cells were evident by day
21. There were no obvious differences among the
groups. These data indicate that FTY treatment
in vivo did not impair the differentiation capacity of
CLPs into early T cells, as assessed by culture on
OP-9DL cells. Together with previous data, these
data further implicate homing effects as the cause of
the lack of thymopoiesis.Host SP Thymocytes Mediate Delayed Graft
Rejection in FTY-Treated Mice
To further examine the kinetics of rejection, a cohort
of engrafted FTY-treatedmice was evaluated at 7 weeks,
3 weeks after the cessation of FTY. At 7 weeks, engraft-
ment had already decreased from an average of 85% to
6%donor (Figure 6A).High levels of hostCD81Tcells
and host DX51 NK cells in PBL were associated with
this loss of engraftment (data not shown). We hypothe-
sized that on cessation of FTY, fully competent mature
host SP T cells were released from the thymus into the
periphery and mediated delayed rejection of the donor
graft. Given the high levels of circulating host NK cells
seen in rejecting mice, we also believed that recovering
hostNK cells played a role in the delayed graft rejection.
To ascertain the competence of host (B6) SP thy-
mocytes inmediating allogeneic graft rejection,mature
SP thymocytes were obtained from FTY-treated allo-
geneic BMT recipients at 4 weeks after BMT. These
cells were adoptively transferred into B6 recipients af-
ter lethal irradiation on the day before infusion of
BALB/c BM. All 10 recipients receiving the SP thymo-
cytes died of graft rejection by day 15. In contrast, con-
trols not receiving SP thymocytes survived long term
(Figure 6B). These data indicate that the host SP thy-
mocytes from FTY-treated allogenic BMT mice are
capable of mediating donor BM graft rejection.
To further address the rolesofhostTandNKcells in
delayed graft rejection, the experimental design was
modified touseB6 thy1.11 congenicmice asBMTrecip-
ients, which allowed for the selective depletion of host T
cells. B6 thy1.11micewere sublethally irradiated and in-
fused with BALB/c thy1.21 BM cells. Mice received
FTYdaily for 4weeks.At 1month, high-level donor chi-
meras (all but 1.95%donor byPBLphenotyping)were
randomly divided into 4 groups receiving no antibody,
anti-thy1.1 mAb to selectively deplete host T cells,
anti-NK1.1 mAb to selectively deplete host NK cells,
or both anti-thy1.1 and anti-NK1.1 mAbs. Consistent
with previous data, 17 of 18 mice receiving no antibody
demonstrated graft rejection by 3months.Mostmice re-
ceiving anti-NK1.1 mAb experienced graft rejection,
with only 3 of 12 retaining low levels of donor engraft-
ment at 3 months. In contrast, all mice receiving anti-
thy1.1 alone or in combination with anti-NK1.1
remained high-level (.98%) donor chimeras for 9
months (Figure 6C and data not shown). These data in-
dicate that host T cells, likely released from the thymus
after discontinuation of FTY, were necessary and suffi-
cient to mediate delayed graft rejection.In Combination with Anti-CD40L mAb, FTY
Stably Increases Donor Chimerism in
Nonmyeloablated Recipients
Although FTY as a single agent did not permit
stable long-term chimerism after discontinuation of
Figure 5. Donor CLPs from FTY-treated mice can differentiate into T cell progenitors in in vitro cultures. B6 mice were irradiated with 5.0 Gy TBI on
day 21 and infused with 10  106 TCD allogeneic BALB/c BM on day 0. To ensure an engrafted BMT control, anti-CD4 and anti-CD8 mAbs were ad-
ministered on day22, day 0, and day14 (designated TCD). FTY was administered on day 0 to day 28. A non-BMT BALB/c control was included. On day
29, BM from mice with.92% donor PBLs was harvested from femurs, tibiae, and spines (pool of 10 mice/group), depleted of host lineage-positive cells,
and sorted for donor1lineage2skitloSca-1lo CLP cells. CLPs were cultured on a BM stromal cell line, OP-9DL1, that permits T cell lineage commitment
and early T cell differentiation, and phenotyped on the indicated day of culture. Shown is a CD44/CD25 contour plot illustrating maturation from stage
DN1 to stage DN4 of T cell development. No significant differences in cell yield are seen.
1348 Biol Blood Marrow Transplant 18:1341-1352, 2012P. A. Taylor et al.FTY, chimerism during FTY administration was
markedly increased. Thus, we sought to combine
FTY with a tolerigenic agent to attempt to convert
the chimerism status to a stable state on cessation of
FTY. Our group and others have shown previously
that anti-CD40L mAb facilitates alloengraftment and
tolerance induction under nonmyeloablative condi-
tioning [18,22-27]. We hypothesized that the
combination of FTY and anti-CD40LmAbmight per-
mit high-level, stable donor chimerism beyond that of
anti-CD40LmAb alone by virtue of FTY’s positive ef-
fect on donor BM stem cell homing and anti-CD40L
mAb’s effect on inducing tolerance. B6 recipients
were given low-dose TBI (1.0 or 2.0 Gy) on day 21
and infused with BALB/c BM cells on day 0, followed
by a 4-week course of FTY, anti-CD40L mAb, or
both. Although FTY alone did not enhance donor chi-
merism inmice receiving low-doseTBI, the addition of
FTY to anti-CD40L mAb increased donor chimerismfrom 31% to 50% at 5weeks and from 56% to 73% at 4
months in mice conditioned with 2.0 Gy (Figure 7A).
At 1.0Gy, the addition of FTY to anti-CD40LmAb in-
creased donor chimerism from 18% to 48% at 5 weeks
and from 28% to 56% at 4 months (Figure 7B). Al-
though T cells were reduced in PBLs at 5 weeks in
the FTY-treated mice, donor and host T cells were
present at 4 months, indicating resumption of normal
donor and host thymopoiesis in the mixed chimeric
mice after cessation of FTY (Figure 7C and D). More-
over, mice receiving both FTY and anti-CD40L mAb
had a higher proportion of donor T cells than those re-
ceiving only anti-CD40L mAb (Figure 7C and D).
Mice remained durably engrafted in T cell, B cell,
andmyeloid cell lineages for the 10-month observation
period (data not shown). These data illustrate that the
combination of FTY and anti-CD40L mAb can aug-
ment donor chimerism and support stable, long-term,
multilineage allogeneic engraftment.
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Figure 6. Host SP T cells mediate delayed graft rejection in FTY-treated engrafted mice. (A) PBLs from FTY-treated mice were phenotyped at 4 weeks
and 7 weeks after BMT. Shown is the decline in engraftment in each mouse from 4 weeks to 7 weeks. n5 16 mice; P\.001, 4 weeks versus 7 weeks. (B)
On day 28 after transplantation, 0.5  106 mature B6-type SP thymocytes isolated from FTY-treated allogeneic BMTrecipients were adoptively trans-
ferred into B6 hosts immediately after lethal irradiation and 1 day before infusion of BALB/c BM. Survival is shown. Mice receiving thymocytes died of
graft rejection by day 15, whereas those not receiving thymocytes survived long term. n 5 8 mice/group; P\.001. (C) B6 thy1.1 mice were irradiated
with 5.0 Gy TBI on day 21 and infused with 10  106 TCD allogeneic BALB/c thy1.2 BM on day 0. Mice received FTY daily for 4 weeks. High-level
chimeras received either no Ab, anti-NK1.1 mAb to deplete host NK cells, anti-thy1.1 mAb to deplete host T cells, or both anti-NK1.1 and anti-
thy1.1 mAbs. Percent donor engraftment at 4 weeks and 3 months is shown. n5 12-18 mice/group; P\.001, 4 weeks versus 3months for mice receiving
no Ab or anti-NK1.1 mAb.
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The major finding of the present study is that
FTY used as a single agent only transiently increased
allogeneic BM engraftment in sublethally irradiated
mice without inducing tolerance. Although FTY pro-
moted the migration and homing of donor progenitor
BM cells to the host BM cavity, resulting in high levels
of donor engraftment in the B cell, myeloid cell, and
NK cell lineages, donor T cell progenitors within
the thymus were nearly absent, resulting in a lack of
donor T cell reconstitution. Moreover, FTY seques-
tered fully functional host SP T cells in the thymus
that on cessation of FTY were able to exit from the
thymus and mediate a rapid rejection of the well-
established donor BM graft in most mice.
Other engraftment-promoting strategies that
we have studied (eg, anti-CD40L mAb, rapamycin, and
CD41CD251 regulatory T cells) always resulted in
stable, long-term engraftment; thus, the loss of
well-established grafts in the FTY-treated mice was sur-
prising [26,28-31]. However, those strategies relied on
the inhibition of host antidonor responses and
simultaneously permitted normal donor thymopoiesis
and early donor T cell reconstitution of the periphery.Furthermore, newly minted donor T cells might be
expected to assist in the tolerization of any potentially
wayward residual host T cells. In contrast, FTY is
known to modulate the homing and migration of many
different cell types, but it does not impair the activation,
proliferation, and effector functions of T cells per se [1].
Therefore, on cessation of FTY, the migration blockade
was lifted, and fully functionalhost antidonorTcellswere
capable of mediating a rapid and thorough unrestrained
elimination of all donor cells in most mice.With the lift-
ing of the migration blockade and the destruction of do-
nor cells, host ETPs were able to enter the thymus, and
normal host thymopoiesis resumed. Although our data
attribute the loss of donor grafts mainly to the host SP
cells newly released from the thymus on cessation of
FTY, it is likely that the hostTcells in theBM, secondary
lymphoid organs, and the periphery also contributed to
delayedgraft rejection. Inanycase, thecomplete rejection
of a seemingly well-established donor graft illustrates the
potency of a dormant host antidonor T cell response.
Moreover, the fact that FTY could hold that response
in check until it was withdrawn is a powerful illustration
of its profound migration and homing modulating
effects.
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Figure 7. FTY stably increases the anti-CD40L mAb-mediated alloengraftment promoting effect in mice receiving low-dose TBI. B6 mice were irra-
diated with 2.0 Gy (A and C) or 1.0 Gy (B and D) TBI on day21 and infused with 40 106 non-TCDBALB/c BM on day 0. FTY, anti-CD40L, or both was
administered for 4 weeks. (A,B) PBLs were phenotyped for percentage of donor cells at 5 weeks and 4 months. (C,D) The percentage of donor and host
T cells (CD41 plus CD81) in PBLs at 4 months is shown. (A and C) n 5 10 mice/group; 1 experiment. (B and D) n 5 20 mice/group; pool of 2 exper-
iments. *P\.05, anti-CD40L versus FTY plus anti-CD40L; P^ 5 .06, anti-CD40L versus FTY plus anti-CD40L. Data are mean 6 1 SEM.
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FTY reported in this study are in contrast to the results
of our previous study reporting GVHD inhibition by
FTY. In that earlier study, we found that FTY differ-
entially and transiently modified GVHD effector T
cell migration to lymphoid organs but did not
profoundly trap effectors in LNs or prevent early
effector T cell migration into GVHD target parenchy-
mal organs. We speculate that the higher irradiation
dose, increased levels of proinflammatory cytokines,
destruction of lymphoid architecture, tissue destruc-
tion, and chemokine perturbation associated with
GVHD renders allogeneic effector T cells less suscep-
tible to profound migration modulation by FTY. It is
also possible that the highly activated state of the
GVHD effector T cells inherently makes them less
governable by FTY. Thus, the magnitude of FTY’s
migration modulating effects depends on the experi-
mental design in which it is studied.
Importantly, FTY was of significant additive ben-
efit when used in conjunction with anti-CD40L mAb
in nonmyeloablated allogeneic recipients, and in that
context, engraftment was multilineage, stable, and
long term. FTY increased the number of donor stem
cells homing to the BM compartment, and although
we did not directly address this, we hypothesize thatengraftment was stable in mice receiving anti-
CD40L mAb and FTY because anti-CD40L mAb
tolerized the mature host T cells remaining after con-
ditioning, and host-type T cells arising after BMT
would be tolerized to the donor on development in
the thymus. Thus, the addition of anti-CD40L mAb
to FTY abrogated the rapid host T cell rejection of
the donor graft after FTY cessation, permitting both
donor and host T cell progenitors to enter the thymus
and allowing the resumption of donor and host thymo-
poiesis.
FTYhasbeen shown to supportCXCR4-dependent
migration andBMhoming ofCD341 stem cells [10,21].
CXCR4, expressed on hematopoietic stem cells, is the
receptor for stromal cell–derived factor 1, expressed by
endothelial cells and the endosteum of the BM cavity
[10]. The interaction between stromal cell–derived fac-
tor 1 and CXCR4 further activates adhesion molecules
that contribute to stem cell homing [32-34]. Thus,
FTY directly and indirectly promotes BM homing of
infused donor stem cells, resulting in increased levels
of donor chimerism in both allogeneic and congenic
recipients. For congenic recipients, there was no host
antidonor T cell response to mediate delayed graft
rejection, and engraftment was stable. For allogeneic
recipients receiving FTY and anti-CD40L, we
Biol Blood Marrow Transplant 18:1341-1352, 2012 1351FTY in Engraftmenthypothesize that host antidonor T cells were tolerized,
and engraftment was stable. Therefore, it is possible
that FTY could be exploited for its benefit in increasing
BMhoming of infused progenitor cells if combinedwith
a reagent that can tolerize host antidonor T cell
responses.
In summary, we have demonstrated that FTY pro-
moted donor stem cell homing to the host BM cavity
and prevented the thymic ingress of T cell progenitors
and the thymic egress of SP thymocytes under non-
myeloablative conditioning in allogeneic BMT recipi-
ents. These important findings suggest that FTY used
as a single agent in irradiated allogeneic BMT recipi-
ents may predispose these recipients to a state of T
cell immune deficiency until thymopoiesis is reset after
cessation of FTY administration. A novel aspect of this
study lies in the determination of what the migratory
effects of FTY would mean to nonmyeloablated allo-
geneic BMT recipients with respect to initial engraft-
ment and engraftment stability. The complications of
sublethal TBI and host antidonor T cell immune re-
sponses precluded easy predictions based on studies
conducted largely in normal controls who did not un-
dergo transplantation.
Because FTY as a single agent was not tolerigenic
and graft rejection resulted after discontinuation of
FTY, this study introduces a note of caution in the
clinical use of FTY as a single agent in the context of
nonmyeloablative conditioning. However, combined
with anti-CD40L mAb, FTY results in high levels
of stable multilineage alloengraftment in nonmyeloab-
lated recipients. Moreover, the combination of
anti-CD40L mAb and FTY has stronger GVHD-
inhibiting effects than FTY alone (data not shown).
Thus, the coadministration of FTY with anti-CD40L
mAb may provide an approach to achieving GVHD
inhibition with high levels of stable alloengraftment
in BMT recipients susceptible to the dual complica-
tions of graft rejection and GVHD.ACKNOWLEDGMENTS
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